Our Company2019-04-12T14:32:58+00:00

Our Company

Amylyx Pharmaceuticals was founded in 2013 with the mission of improving the lives of patients with neurodegenerative diseases. The company’s lead therapeutic, AMX0035, is designed to simultaneously target pathways originating in the mitochondria and endoplasmic reticulum which lead to neuronal death and degradation. AMX0035 is currently in clinical trials in both Alzheimer’s disease and ALS.

The company is focused on evaluating AMX0035 in these indications and, if successful, intends to rapidly provide it to patients in need.

Executive Team

JOSH COHEN

CEO and Co-Founder

JUSTIN KLEE

President and Co-Founder

KENT LESLIE

Chief Scientific Officer

PATRICK YERAMIAN

Chief Medical Officer

Tom Holmes

Global Head, Supply Chain

LINDA PROCTOR

Quality

BEVERLY LEWIS

CMC Regulatory Affairs

STACY SUBERG

FDA Regulatory Affairs

JEFF WILSON

Pharmaceutical Development & Manufacturing

RUDOLPH TANZI

Chair of the Scientific Advisory Board